HER2 testing recommendations in Australia

Bilous, Michael, Ades, Colin, Armes, Jane, Bell, Richard, Brown, Robert, Cook, Bridget, Cummings, Margaret C., Field, Andrew, Llewellyn, Huw, McKenzie, Paul, Raymond, Wendy, Robbins, Peter and Tan, Lisa (2001) HER2 testing recommendations in Australia. Pathology, 33 4: 425-427. doi:10.1080/00313020120083133

Author Bilous, Michael
Ades, Colin
Armes, Jane
Bell, Richard
Brown, Robert
Cook, Bridget
Cummings, Margaret C.
Field, Andrew
Llewellyn, Huw
McKenzie, Paul
Raymond, Wendy
Robbins, Peter
Tan, Lisa
Title HER2 testing recommendations in Australia
Journal name Pathology   Check publisher's open access policy
ISSN 0031-3025
Publication date 2001
Sub-type Article (original research)
DOI 10.1080/00313020120083133
Volume 33
Issue 4
Start page 425
End page 427
Total pages 3
Place of publication Abingdon, England
Publisher Informa Healthcare.
Language eng
Subject 110306 Endocrinology
Abstract HER2 is the target of a new treatment for metastatic breast cancer using the humanised monoclonal antibody trastuzumab (Herceptin). Since only around 20% of breast cancers carry the overexpressed HER2 receptor protein to which this treatment is directed, patient selection is very important in determining eligibility for the drug. Currently, immunohistochemistry and fluorescence in situ hybridisation are the main tests used for HER2 detection, and these testing recommendations have been developed based on national and international data. © 2001 Royal College of Pathologists of Australasia
Keyword Breast carcinoma
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: Scopus Citation Count Cited 15 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 14 Jul 2010, 14:47:27 EST by Ms Jillian Griffin on behalf of Faculty Of Health Sciences